June 29, 2020

Konica Minolta Precision Medicine (KMPM) Launches Care for COVID Program

The CARE for COVID Program, led by KMPM company Ambry Genetics, helps employers address critical challenges surrounding COVID-19 testing, including helping determine who can return to work, who should be tested, the frequency of employee wellness checks, and test type.

(Aliso Viejo, CA) June 29, 2020: Ambry Genetics Corporation (Ambry), a leading clinical genetic testing laboratory, announced the launch of its CARE for COVID Program to provide employers with the system, tools, and support they need to screen, test, and manage their employees’ health with respect to COVID-19 as they return to work.

Leveraging the existing Ambry CARE Program ™, which currently enables hereditary cancer risk-assessment at scale, the CARE for COVID Program helps employers make informed decisions about which employees to test, and how frequently, using an online symptom and exposure questionnaire based on the latest CDC guidelines and recommendations. Ambry is developing a comprehensive testing portfolio to integrate within the CARE for COVID Program to create a comprehensive end-to-end screening, testing, and employee health-management solution. Ambry’s initial test offering will be a saliva RT-PCR test for active COVID-19 infection detection, with incremental test options to be rolled out shortly thereafter, and will include point-of-care antigen testing.

An AI-based virtual assistant enables employees to answer the screening and exposure questionnaire from their computers, tablets, or mobile phones to assess the risk of returning to work, and to guide them to the appropriate tests.

“To aid in employee safety, return-to-work initiatives, and general peace of mind, employers need a clinically validated, comprehensive, and cost-effective approach. The CARE platform is that turn-key solution from screening to testing that helps provide a safe work environment and limit potential exposure,” Ambry Chief Executive Officer Aaron Elliott said. “We can tailor our CARE for COVID Program to meet employers’ individual needs as employees return to work and to support continued employee health and wellness.”

The CARE for COVID Program follows a simple process. Ambry’s Virtual Assistant (AVA) guides employees through the online exposure and screening questionnaire, after obtaining their consent, educating them on the process, and guiding them through the questions. Once completed, the employee will be notified whether they should consider testing, and they provide employers information to help them assess whether the employee should return to work. The CARE for COVID Program also includes a HIPAA-compliant portal for employers to track employee completion status. In later versions, the Program plans to offer workplace exposure tracking, helping to quickly identify additional employees who may be at risk and flagging them for testing to help reduce further spread of the virus.

The CARE for COVID Program incorporates the latest guidance from federal agencies, including the CDC. Ambry worked directly with noted experts in academia, industry, and government to develop the program.

The CARE for COVID Program can be customized depending on each organization’s needs.

“We recognize that every business has its own specific needs and concerns as they open up again and that a best-in-class screening and testing program would have to be flexible enough to fit any organization,” Ambry Chief Commercial Officer Tom Schoenherr said. “Our CARE for COVID Program will soon incorporate a portfolio of testing options providing businesses a full view of the landscape of employee health to help ensure that everyone is as safe as possible in the face of the ongoing pandemic.”

The Ambry CARE (Comprehensive Assessment, Risk, and Education) program is a population-health, precision-medicine tool that can be used to address employee health and wellness across a range of medical issues. Already used to help people learn whether they are at risk for hereditary cancers including breast and colon cancers, the program can also be adapted to help employees identify and manage diabetes, cardiovascular, and other diseases. To learn more about the CARE program and hereditary cancer risk, please visit

About Konica Minolta Precision Medicine

Konica Minolta Precision Medicine, Inc. (KMPM) is a comprehensive precision diagnostics company dedicated to advancing technologies that accurately predict, detect, and treat disease. Powered by proprietary software platforms, best-in-class genomics technology from Ambry Genetics Corporation, and industry-leading radiology and pathology services from Invicro, LLC, KMPM is uniquely equipped to collect, analyze, and report on multi-modal precision diagnostic data sets. This comprehensive approach will drive clinical access to novel diagnostic assays through the company's extensive network of healthcare providers and pharmaceutical partners.

Press Contact:
Olivia Duarte
(949) 457-4335